Canada· CA-DIN-02441829
TOUJEO SOLOSTAR
A insulin glargine product containing insulin glargine, registered in Canada by SANOFI-AVENTIS CANADA INC. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Insulin glargine is registered in 13 of 19 countries.
Countries holding a registration under ATC A10AE04 (insulin glargine), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Insulin glargine · ATC A10AE04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- INSULIN GLARGINE
- Manufacturer
- SANOFI-AVENTIS CANADA INC
- Country
- Canada (CA)
- ATC code
- A10AE04
- ATC class
- Insulin glargine
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
433 interactions on record for insulin glargine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin glargine · interactions on record
433 records
- 15 severe
- 367 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Insulin glargine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaABASAGLAREli Lilly Nederland B.V., Utrecht
- United KingdomAbasaglar 100units/ml solution for injection 3ml cartridgesEli Lilly and Company Ltd
- United StatesBASAGLAREli Lilly and Company
- BelgiumAbasaglar 100 U/mlEli Lilly Nederland
- FinlandABASAGLAREli Lilly Nederland B.V.
- SpainABASAGLAR 100 UNIDADES/ML KWIKPEN SOLUCION INYECTABLE EN PLUMA PRECARGADAEli Lilly Nederland B.V.
- IrelandABASAGLAR 100 units/mL solution for injection in a cartridgeEli Lilly Nederland B.V.
- SwedenABASAGLAR 100 enheter/ml Injektionsvätska, lösning i cylinderampullEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Abasaglar, Abasaglar Kwikpen
- Liechtenstein · Abasaglar, Abasaglar Kwikpen
- Norway · Lantus, Lantus Solostar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d9d35dd6-09f6-4c1f-ac68-77c81a04afbf GET /v1/drugs/d9d35dd6-09f6-4c1f-ac68-77c81a04afbf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02441829",
"form": "SOLUTION",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "A10AE04",
"schedule": [
"Schedule D"
],
"drug_code": "92621",
"strengths": [
"300 UNIT"
],
"ahfs_class": null,
"substances": [
"INSULIN GLARGINE"
],
"product_categorization": null
}See everything about insulin glargine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.